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Unexplained Symptoms after
Events of Public Health
Concern
In the early days of industrialization, risks and
hazards were evident to the senses—they could be
smelt, touched, tasted or observed with the naked
eye. In contrast, many of the major risks today
largely escape perception. . . . These risks exist in
scientiﬁc knowledge rather than everyday experi-
ence. — Sociologist Deborah Lupton [(1); p. 64)]
Medically unexplained physical symptoms
(MUPS) have been deﬁned as physical symp-
toms that prompt the sufferer to seek health-
care but remain unexplained after an
appropriate medical evaluation (2). MUPS
are perceptual (a person feels symptoms), cog-
nitive (the person experiencing symptoms
decides they are either ominous or benign),
and behavioral (e.g., if the person decides the
symptoms are ominous, he or she usually
seeks healthcare for them). Studies show that
MUPS are nearly ubiquitous—conservative
estimates suggest that a fourth to a third of
physical symptoms in the general population
and in primary care settings are medically
unexplained (3,4).
Chronic fatigue syndrome (CFS),
ﬁbromyalgia syndrome (FMS), and multiple
chemical sensitivities (MCS) are among a
growing number of symptom syndromes
acknowledged as medically unexplained
(2,5–13). Several investigators have noted
that these and other MUPS syndromes have
overlapping phenomenology (7,8,12–15),
pathophysiology (12), risk factors (7), pre-
dictors of outcome (7), and effective thera-
pies (5,7,11). Most argue in various ways
that these MUPS syndromes are heteroge-
neous groupings of symptoms that merge
into a single diffuse construct with unclear
clinical boundaries—MUPS (6,9). Even
though MUPS are unexplained, they are not
trivial—they are consistently and strongly
associated with impaired functioning,
psychosocial distress, and treatable anxiety
and depressive disorders (4,16,17).
Epidemiologic studies find that MUPS
are so common that we should expect that
they would occur after all events or exposures
that affect any modest-sized group of people.
When MUPS occur after significant events
involving environmental exposures, particu-
larly if they are noticeable and impressive, the
affected individual often reflects back in
search of causes and then links MUPS to
these worrisome exposures. This occurs even
when the best scientiﬁc evidence suggests that
a causal relationship is unlikely. Some of the
most poignant examples of this have occurred
after military or wartime service (18). In the
early to mid-1990s, for example, veterans of
the Gulf War developed MUPS, leading to
questions regarding the possible presence of a
Gulf War syndrome due to hazardous battle-
field exposures (19). After World War I,
many returning veterans described chronic
debilitating physical symptoms and attributed
them to chemical exposures incurred during
months of trench warfare (20). After the
Vietnam War, hundreds of thousands of vet-
erans sought evaluation for concerns related
to Agent Orange (dioxin) exposure (21).
Other examples in military personnel
have occurred outside the context of war.
MUPS became a focus of concern following
mandated military vaccinations in the United
States and United Kingdom (22). MUPS
were a concern among Canadian peacekeep-
ers after duty in Croatia, and many linked
their symptoms to ruddy soil they encoun-
tered at one encampment (23). Apprehension
regarding the relationship between low-level
depleted uranium exposures and a possible
“Balkan War syndrome” recently received
worldwide attention (24). In the 1980s
Dutch peacekeepers in Cambodia developed
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Unexplained Symptoms
Medically unexplained physical symptoms (MUPS) are persistent idiopathic symptoms that drive
patients to seek medical care. MUPS syndromes include chronic fatigue syndrome, ﬁbromyalgia
syndrome, and multiple chemical sensitivities. When MUPS occur after an environmental expo-
sure or injury, an adversarial social context that we call “contested causation” may ensue.
Contested causation may occur publicly and involve media controversy, scientific disagreement,
political debate, and legal struggles. This adversarial social context may diminish the effectiveness
of the provider–patient relationship. Contested causation also may occur privately, when disagree-
ment over the causes of MUPS takes place in the patient–provider context. These
patient–provider disagreements over causation often occur because of the enigmatic nature of
MUPS. We suggest that a context of contested causation may have serious negative effects on
healthcare for individuals with MUPS. Context plays a larger role in MUPS care than it does for
most medical care because of the uncertain nature of MUPS, the reliance of standard MUPS ther-
apies on a potentially tenuous patient–provider partnership, and the clinical need to rely routinely
on subjective MUPS assessments that often yield discordant patient and provider conclusions.
Contested causation may erode patient–provider trust, test the provider’s self-assurance and capac-
ity to share power with the patient, and raise problematic issues of compensation, reparation, and
blame. These issues may distract patients and providers from therapeutic goals. In occupational
and military settings, the adverse impact of contested causation on the patient–provider partner-
ship may diminish therapeutic effectiveness to a greater degree than it does in other medical set-
tings. Contested causation therefore raises questions regarding generalizability of standard
therapies for MUPS and related syndromes to these settings. Future research is needed to learn
whether intuitively sensible and evidence-based MUPS therapies beneﬁt occupational and military
medical patients who are afforded care in the context of contested causation. Key words: chronic
fatigue syndrome, environmental, fibromyalgia, Gulf War syndrome, medically unexplained
symptoms, military, multiple chemical sensitivity, occupational, somatoform, veterans. Environ
Health Perspect 110(suppl 4):641–647 (2002).
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MUPS that became known popularly as
“jungle disease” (25).
MUPS after environmental exposures of
civilian populations have demonstrated that
this issue is larger than military service and
war. Examples include the 1979 threat of
nuclear accident at Three Mile Island near
Harrisburg, Pennsylvania (26), industrial
waste exposures at Love Canal in Niagara
Falls, New York, in the 1970s (27), exposures
to implanted silicone medical devices (28),
and possible toxic exposures from a jetliner
crash in a populated area of Amsterdam (29).
After the 11 September 2001 terrorist attack
on the World Trade Center in New York
City, concerns of a “WTC syndrome” con-
sisting of cough, indigestion, eye irritation,
and other symptoms emerged (30). Follow-
up among survivors of the October 2001
anthrax attacks in the United States have
uncovered persistent MUPS among handlers
of mail that was irradiated to eliminate possi-
ble anthrax spores (31,32).
We do not cite these examples in an effort
to diminish the medical signiﬁcance of corre-
sponding environmental exposures. To the
contrary, many if not most of these exposure
events are known to involve harmful environ-
mental toxins. Instead, in this article we
describe how the contentious social context
that often follows these exposures may
adversely affect healthcare delivery for
MUPS. Context has a greater opportunity to
directly affect medical care for MUPS than it
does for more readily diagnosed diseases. We
will show that the impact may be greater
because of the uncertain nature of MUPS, the
reliance of standard MUPS therapies on a
potentially tenuous patient–provider partner-
ship, and the clinical need to rely routinely on
subjective MUPS assessments, assessments that
often yield discordant patient and provider
conclusions about patient health status.
Social Context, Contested
Causation, and Unexplained
Symptoms
In the quotation opening this article, Lupton
(1) suggests that today’s major environmental
health threats are often imperceptible. MUPS
are mysterious in that affected individuals
perceive them, but objective evidence proving
their existence is elusive. For those who expe-
rience MUPS, the symptoms are all too real,
and patients with MUPS are generally impa-
tient with anyone who doubts the veracity of
their symptom reports. Perhaps, therefore, it
is not surprising that patients with MUPS
sometimes connect their symptoms to unseen
environmental exposures.
Social context may adversely affect the
health of patients with MUPS when toxic
exposures with plausible health consequences
become a matter of media attention, high-
profile scientific discussion, political debate,
wide-ranging litigation, or doctor–patient dis-
agreement. These relatively adversarial cir-
cumstances may be described as “contested
causation.” Contested causation may
adversely affect MUPS-related healthcare at
both the public and private levels. Contested
causation is public when it involves popula-
tion-level stakeholder conflicts. This type of
contested causation occurs when scientists
publicly disagree over evidence supporting or
refuting linkages between MUPS and envi-
ronmental exposures of wide concern, when
large-scale litigation such as class action suits
focuses on issues of responsibility and blame
for the health effects of environmental expo-
sures, or when political debate involves rancor
between polarized adversaries. In publicly
contested causation, the popular media often
play a large role in disseminating the details
of adversarial discussions.
Contested causation is private when
patient–provider disagreements regarding
cause occur because of the inscrutable nature
of MUPS. An extensive literature suggests
that in the absence of associated ﬁndings on
physical examination or clinical testing,
providers frequently conclude that MUPS are
“minor” and less compelling than when they
occur in association with an identiﬁable dis-
ease. In the privacy of the patient–provider
relationship, the provider may reject or even
directly dispute the patient’s beliefs regarding
causation (33). Many providers view MUPS
as manifestations of an underlying psycholog-
ical problem, whereas most patients reporting
MUPS ﬁnd psychological explanations belit-
tling. Different providers, especially those
from different medical specialties, may vary
widely in their conclusions regarding causa-
tion and treatment for a given patient with
MUPS. Provider differences can add to
patient confusion and possibly increase the
likelihood of subsequent patient–provider
diagnostic disagreements (34).
Our notion of privately contested causa-
tion is partly based on Hadler’s (35) descrip-
tion of an iatrogenic doctor–patient “contest”
(as he noted, “It is hard, if not impossible, to
get well if you have to prove that you are
sick”) (35,36) Brown and colleagues’s
(37–39) description of “popular epidemiol-
ogy” has strongly inﬂuenced our conceptual-
ization of publicly contested causation.
Brown, a sociologist, described popular epi-
demiology as the manner in which lay mem-
bers of environmentally “contaminated
communities” (e.g., Love Canal, New York;
Woburn, Massachusetts; and U.S. Gulf War
veterans—the latter being a community
joined by perception of a common experience
rather than location) have organized to con-
test the “dominant epidemiologic paradigm”
(i.e., empiricism and scientific authority).
Our concept of contested causation is also
developed from Mazur’s (27) inventive use of
the movie Rashomon, a 1950s depiction of an
ancient Japanese fable, to illustrate how dif-
ferent stakeholders involved in Love Canal
environmental exposure investigations even-
tually arrived at equally plausible but
markedly different and adversarial perspec-
tives of the same events and studies.
Dembe (40), a sociologist and occupa-
tional health services researcher, has per-
formed an extensive historical examination of
the social factors determining how occupa-
tional illnesses are recognized. He found his-
torical evidence for the impact of social
context on the patient–provider relationship,
particularly for illnesses involving multifactor-
ial pathogenesis. Dembe pointed out that for
illnesses occurring via complex or poorly
understood causal pathways, a clinical deter-
mination of occupational relatedness is less
than straightforward. For example, some
causal factors may reside inside but not out-
side the workplace, other causal factors may
reside outside but not inside the workplace,
and still other causal factors reside both inside
and outside the workplace (40).
The central thesis of this article is that in
the context of contested causation, healthcare
for MUPS may be adversely affected. These
adverse effects of contested causation may
manifest in any healthcare setting, are proba-
bly greater in occupational and military med-
ical settings, and may affect whether the
results of MUPS treatment research studies
done in general treatment settings can be gen-
eralized to occupational or military settings.
Patients, Providers, MUPS
Treatment, and Symptom-
Related Disability
Alleviating discomfort due to symptoms has
long been a central focus of Western medicine.
Indeed, relatively few therapies in medicine are
curative. Symptoms are a major source of dis-
ability among patients with MUPS and those
with well-deﬁned diseases (Figure 1) (41), and
some have argued that rehabilitative therapies
targeting symptom-related disability may pro-
vide a model for making systemwide improve-
ments in general healthcare delivery.
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Figure 1. A causal model describing the relation-
ship of biomedical (or disease) status and symp-
toms to functional status, perceived health, and
overall quality of life. Modified from Wilson and
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As Figure 1 suggests, chronic symptoms
from any cause (pain is the prototype) can
lead to decreased health-related quality of
life via at least three mechanisms: a) reduced
tolerance for physical activity, b) distress and
depressive and anxiety disorders that impair
relationships and reduce social functioning,
and c) diminished ability to fulfill key roles
such as wage earner, spouse, or parent
because of decrements in physical and men-
tal health functioning. These mechanisms
compound one another, creating a cycle of
decreasing functioning, increasing risk fac-
tors for poor health (e.g., obesity, hyperten-
sion, smoking, drinking, and loss of social
supports), increasing incident disease,
increasing symptoms, and even causing
greater decrements in functioning. Our
group has found that MUPS are associated
with small but measurable elevations in
mortality, even after controlling for a num-
ber of potentially confounding mental and
substance use disorders (42).
Two rehabilitative therapies (interventions
usually based on behavioral principles that are
administered to improve functioning and
reduce disability), graduated physical activity
(GPA) and cognitive-behavioral therapy
(CBT), are empirically supported approaches
for MUPS and related syndromes (5,11,
43–45). The finding to date that different
MUPS syndromes respond to similar thera-
peutic strategies is consistent with the theoret-
ical model presented in Figure 1 and suggests
that MUPS after environmental exposures
may be treated early using these modalities
until more definitive biomedical approaches
are identiﬁed scientiﬁcally. This rationale was
used to select candidate therapies for evalua-
tion in controlled trials involving Gulf War
veterans with MUPS (10,46,47).
We now briefly review GPA and CBT
and then turn to the centrality of the patient–
provider relationship in these therapies.
Graduated Physical Activity
Physical activity has important physical and
psychological impacts on health and well-
being (48,49). Structured approaches to GPA
improves outcomes for a wide range of ill-
nesses such as chronic low back pain (50,51),
depressive disorders (52), diabetes mellitus
(53), multiple sclerosis (54), and even cancer
patients in chemotherapy (55). Several studies
of CFS and FMS have determined that GPA
improves global symptoms, including pain
(56–61). Reid et al. (44) noted that there is
considerable indirect evidence suggesting that
bed rest, the opposite of exercise, is harmful.
GPA may improve symptoms and function-
ing by increasing strength, decreasing fatigue,
and increasing endogenous opioids (62).
Exercise can also improve well-being, sense of
control, and mood (52,63,64).
Physical activity for MUPS requires a
tailored, flexible, and graduated approach.
Rapid introduction of strenuous exercise can
exacerbate symptoms and reduce subsequent
adherence to physical activity (65). Decisions
regarding how and when to resume work are
important, too. An early return to work gen-
erally serves to bolster role functioning and
self-esteem. A supervised, graduated return to
work-related activities is most necessary for
jobs with physical conditioning standards.
Rapid return to supervisory and other non-
physical roles may offer patients opportunities
for early success and reinforce co-worker
expectations of a full recovery. In contrast,
rapid return to strenuous job-related physical
activities is discouraging and self-defeating for
most patients.
Particularly in occupational and military
healthcare settings, policies that support grad-
uated levels of increasing responsibility and
activity after injury or illness may improve
rates of successful return to full occupational
function. We would predict that a return-to-
work policy based on the presence or absence
of a disease is more likely to result in unrealis-
tically rapid attempts at resuming physical
functioning for MUPS and frequent failure to
promote gradual increases in physical activity
and role functioning in patients with diseases.
Cognitive-Behavioral Therapy
Most studies have found CBT to be effective
for a wide range of MUPS, including FMS,
CFS, and irritable bowel syndrome
(11,66,67). CBT stems from the theory that
symptoms and poor functioning occur
because of a complex integration of patho-
physiology, cognition, affect, and behavior
(68,69). The aim of CBT is 2-fold: a) to
facilitate a safe and graduated improvement
in functioning without exacerbating symp-
toms and b) to jointly examine problems and
beliefs in an effort to negotiate solutions,
identify and revise harmful beliefs, and adopt
active coping strategies.
Common components of CBT are time-
contingent activity pacing, pleasant activity
scheduling, sleep hygiene, assertiveness skills,
self-examination for harmful or negative
thinking, and structured problem-solving
skills. These strategies, alone or in combina-
tion, have been used successfully to improve
functioning among patients with MUPS and
other chronic illnesses (70–78).
Figures 2 and 3 summarize this short dis-
cussion of rehabilitative approaches to
MUPS. Figure 2 explicates key causal path-
ways by which MUPS lead to reductions in
health status. Pathways involving harmful
health beliefs and health behaviors are promi-
nent and lead to psychosocial distress and
increasing disability. Figure 3 illustrates that
CBT and GPA act on all four of these areas,
leading to improvements in health status in
individuals with MUPS.
The Patient–Provider Relationship 
in Successful MUPS Care
The success of GPA and CBT hinges on a
cooperative patient–provider relationship.
Any clinical intervention, of course, calls for
providers to help patients change health
behaviors. For example, even a simple
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Figure 2. Causal pathways by which MUPS may lead to reduction in health status. Pathways involving
harmful health beliefs and health behaviors are prominent and lead to psychosocial distress and increas-
ing disability.
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Figure 3. Mechanisms by which CBT and GPA mitigate the impact of harmful health behaviors, harmful
beliefs, decreased functioning, and increased psychosocial distress on health status among people with
MUPS (dashed lines represent mitigating effects of the therapies).curative therapy such as an antibiotic for a
minor infection requires the patient to adhere
to a medication prescription. However, per-
suading a chronically ill patient to embark on
a physical activity program or a patient with
low back pain (often viewed by the patient as
physical disease) to adhere to CBT (often
viewed by the patient as “psychotherapy”)
requires well-developed provider communica-
tion skills and a high level of patient and
provider conﬁdence in one another.
Von Korff et al. (79) deﬁne collaborative
management of chronic illness as “care that
strengthens and supports self-care in chronic
illness while assuring that effective medical,
preventive, and health maintenance interven-
tions take place.” Key elements of collabora-
tive management that they outline include
a) collaborative provider–patient deﬁnition of
problems; b) negotiated targeting, goal set-
ting, and planning on the basis of both the
importance of the problem and patient moti-
vation and readiness for self-care; c) creating a
continuum of self-management training and
support services; and d) active, sustained
follow-up. Components of collaborative self-
management training such as GPA and CBT
require joint patient–provider negotiations to
deﬁne goals, priorities, and outcomes of inter-
est. The provider must often inspire and sup-
port patients through extended behavioral
change. This requires regular follow-up,
demonstrations of ongoing provider commit-
ment to the patient, regular reassessment of
treatment goals, and joint problem identiﬁca-
tion and problem solving. Contested causa-
tion erodes the foundation for these efforts,
the collaborative patient–provider partnership.
Contested Causation and 
MUPS Care in Occupational 
and Military Settings
Von Korff et al. recommended a system-level
approach to enhancing collaborative care of
chronic illness (79). Their recommendations
were to a) implement performance indicators
and incentives that motivate improved care;
b) seek science-based technical assistance to
disseminate research findings and effective
programs; c) develop and implement practice
guidelines and clinical information systems;
and d) involve employers, community organi-
zations, government, and patient advocacy
organizations in efforts to improve care. Since
1994, the U.S. Department of Defense
(DoD) healthcare system has pursued this
approach to improve health services for
MUPS and other postdeployment health con-
cerns. That year, the DoD Comprehensive
Clinical Evaluation Program, a diagnostic
evaluation and clinical registry, was initiated
to address MUPS and other health concerns
among Gulf War veterans. In 1999, the
DoD effort was expanded to include all
military-related health concerns and MUPS,
and our group has been at the center of
these efforts. At issue, however, is whether
there is adequate evidence to conclude that a
program of collaborative management for
MUPS can succeed in occupational settings
such as the military.
In 1995 the DoD established a multifac-
eted and interdisciplinary center providing
rehabilitative care for military personnel
reporting persistent and disabling MUPS
after Gulf War service (47). The Deployment
Health Clinical Center at Walter Reed Army
Medical Center in Washington, DC, has
since adapted GPA and CBT to the treat-
ment needs of military personnel, veterans,
and family members with MUPS (46,47).
Pretreatment–post-treatment data from
patients completing this 3-week referral pro-
gram for MUPS show consistent, modest
improvements in participants’ functioning,
symptoms, physical health concerns, and psy-
chological distress lasting at least 3 months
after treatment (47).
In 1998 the U.S. Department of Veterans
Affairs (VA) and the DoD co-sponsored a
randomized controlled trial of GPA and
CBT, and the study is nearing completion.
This study, described in greater detail else-
where (10), compares 1-year health outcomes
for Gulf War veterans with MUPS after
12 weeks of either GPA, CBT, GPA and
CBT, or usual care. Twenty sites and nearly
1,100 veterans have enrolled in the study,
making it the largest study of GPA and CBT
for MUPS to date and the ﬁrst study to eval-
uate these strategies in the occupational
healthcare setting (10).
In 1999 the DoD and VA decided to
develop clinical practice guidelines integrating
lessons learned since the Vietnam era regard-
ing postdeployment healthcare. The DoD-
VA  Clinical Practice Guideline on
Post-Deployment Health Evaluation &
Management (80) and the VA-DoD Clinical
Practice Guideline for the Management of
Medically Unexplained Symptoms: Chronic
Pain and Fatigue (5) are being implemented
starting in 2002. Each of these guidelines has
its own set of performance indicators to iden-
tify implementation successes and gaps.
“Tools” (e.g., assessment measures, patient
and provider education brochures and video-
tapes) have been developed facilitating the
care prescribed in the guidelines. One guide-
line tool is the website “PDHealth.mil”
(http://www.pdhealth.mil), which is open to
the public and provides prompt information
on the health effects associated with military-
related hazards. Also posted on the site are
news media articles that make providers
aware of public information available to
patients that might cause them to seek med-
ical assistance. Goals of the site are to equip
clinicians with near-real-time health informa-
tion and to foster openness between federal
healthcare providers and concerned health-
care system beneﬁciaries.
In 1999, the Deployment Health Clinical
Center became the DoD center of scientific
expertise pertaining to postdeployment
healthcare delivery. In addition to providing
referral clinical services, the center runs con-
tinuing health education programs and health
services research projects that aim to improve
care for MUPS and other military-related
health concerns. The center currently has
health services research projects under way
that are funded by the U.S. National
Institutes of Health, the U.S. Centers for
Disease Control and Prevention, the DoD,
and the VA.
Scientiﬁcally valid research to evaluate the
effectiveness of these comprehensive federal
healthcare programs is a necessity given the
concern that contested causation (and per-
haps structural inﬂuences unique to the fed-
eral healthcare system) may subtly erode the
provider–patient partnership over and above
what occurs in the nonoccupational settings
where previous MUPS treatment studies have
been performed. Next we review possible
mechanisms behind this putative erosion.
Threats to Collaborative
Management Posed by
Contested Causation
Lay people are aware of their dependency on
expert knowledges when it comes to disputes about
risk. They are also aware of their lack of agency
and opportunity, as ‘non-experts’, to challenge
expert knowledges, even if the expert knowledges
are uncertain or conﬂicting. [(1); pp. 110–111]
What reasons exist to think that contested
causation may adversely affect the care of
MUPS? We have illustrated the centrality of
the patient–provider relationship in standard
MUPS therapies. Historical evidence exists,
derived from careful accounts of work-
related diseases, that social context can affect
the patient–provider relationship, particu-
larly in occupational settings (40). This may
occur through any of several overlapping
mechanisms:
• Contested causation may erode patient–
provider trust, mutual respect, and confi-
dence.
• Contested causation, when mixed with the
inherent medical uncertainties surrounding
MUPS, may test provider expertise and
capacity to share power with affected
patients.
•C ontested causation, due to inevitable
questions of compensation, reparation, and
blame, may distract from usual therapeutic
goals.
These mechanisms are not mutually
exclusive, occur to some degree in all medical
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occupational or military healthcare settings.
Figure 4 offers a visual model to show how
contested causation may reduce the effective-
ness of collaborative MUPS management.
Contested Causation and 
the Erosion of Trust
Uncertainty regarding the causation of MUPS
provides greater opportunity for disparate
patient and provider conclusions regarding
legitimate causes. If a patient links his or her
MUPS to a contested cause, appropriate
provider skepticism may turn instead to overt
mistrust of patient motives. Similarly, if a
patient perceives (whether correctly or incor-
rectly) that providers have conﬂicts of interest
that may interfere with their duty to afford
them treatment, patient mistrust for those
providers may result. For example, the patient
may not trust an occupational physician
employed by the workplace if the patient per-
ceives that the physician is protecting the
employer from liability rather than protecting
the workers from medical risk or harm.
Another strain on trust that occurs in all
healthcare settings but is likely to be ampliﬁed
in the occupational and military setting is
patient fear that the provider may label them
with a problem that will follow them in the
workplace and endanger their career. MUPS
after contested causation, therefore, sometimes
create patient doubts regarding provider sin-
cerity and expertise, and provider doubts
about patient veracity and desire to pursue
health improvements.
In the context of contested causation,
other insidious sources of patient–provider
mistrust may exist. For example, the ﬁeld of
environmental risk communication often
teaches that mistrust among concerned par-
ties is heightened in the presence of certain
affect-laden “fear factors” related to the
characteristics of or circumstances surround-
ing suspected environmental exposures (81): 
• Industrial or man-made exposures (vs.
natural exposures)
• Mysterious or poorly understood health
problems such as MUPS (vs. better under-
stood diseases such as diabetes mellitus) (81)
• Real or patient–perceived conflicts of
provider interest (82)
• Patient history of iatrogenic injury (33,83)
In the face of news media stories or high-
proﬁle political power struggles or legal wran-
gling, fear factors may contribute to an overtly
adversarial provider–patient relationship.
Adverse outcomes that result may include
reduced patient adherence, increased provider
frustration, or even mutual rejection (84).
Contested Causation, Provider
Expertise, and Patient–Provider
Power Sharing
Contested causation and its differential
impact on patient and provider explanations
for MUPS may create provider–patient con-
flict and reduce collaboration (85–87). An
optimal patient–provider partnership occurs
when the patient respects the provider’s med-
ical expertise. Although attitudes are chang-
ing, providers remain generally used to
relatively unchallenged clinical authority.
When provider and patient views differ, how-
ever, patients may challenge or question
provider opinions, provider skills, or even the
provider’s claim to special expertise. For
example, a patient may reject a provider’s
expert opinion if it conflicts with personal
experience (88,89). If a patient incorrectly
concludes that a diagnosis of depression
means that the provider believes the patient’s
symptoms are imagined, the patient may
reject the diagnosis and perhaps the provider
because the patient knows with certainty that
the symptoms are valid (88). Regarding
workplace illness or injury, the patient may
feel better informed and more aware of the
potential for environmental exposures than a
provider who does not deal personally with
these risks. These are arguably legitimate
patient claims to personal knowledge, given
that direct evidence in humans regarding the
health effects of many low-dose environmen-
tal exposures is sparse, difficult to interpret,
and subject to methodological uncertainties. 
In the ideal patient–provider partnership,
providers must share control of the therapeu-
tic method and value patients’ knowledge of
their symptoms. However, in the context of
contested causation, these threats to the
provider’s traditional role as medical expert
and authority can trigger defensive provider
responses. Providers may reject patients that
challenge them, or they may invoke patholo-
gizing formulations of patients’ personal
manner as “difﬁcult” and patients’ MUPS as
“psychogenic” (87). In military and occupa-
tional settings, administrative pressures to
reach parsimonious explanations for complex
patient presentations may further amplify
these effects.
Contested Causation May Distract
from Therapeutic Goals
An effective patient–provider partnership
requires both patients and providers to focus
attention on improvement of patient func-
tioning. Scientific controversy, political
debate, and media attention accompanying
contested causation may complicate patient
and provider efforts to maintain a consistent
focus on therapeutic goals. Often, debates
surrounding contested causation implicate
“victims” and “oppressors” or “winners” and
“losers.” These public debates may distract
both patient and provider from therapeutic
goals and may affect provider and patient
beliefs regarding fairness, entitlements, or
need for disability compensation. These
provider and patient perspectives may remain
unspoken, yet they can still dominate the
clinical encounter and distract from efforts to
improve patient health (36).
Societal discourse around contested cau-
sation, responsibility, blame, and reparation
may create predicaments for patients and
providers. For example, patients may perceive
that “getting well” will risk sending the mes-
sage to observers that their illness or injury is
trivial and therefore that compensation is
unneeded. For providers, a common thera-
peutic goal involves encouraging patient
improvements in health behavior and knowl-
edge. However, when compensation is at
issue, providers may instead feel more com-
pelled to provide an exact biomedical
accounting, even if doing so fails to offer
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Figure 4. Contested causation reduces the efﬁcacy of collaborative management of MUPS through ero-
sion of the patient–provider relationship. Contested causation may affect care through private disagree-
ments between patient and provider or through population-based effects resulting from contentious
public discourse occurring after environmental exposures (dotted lines in the foreground represent
contextual effects).
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Patient     Providerdisease-specific therapeutic options. For
example, providers may explain MUPS as
conversion symptoms or a somatoform disor-
der even though it does not lead to specific
therapies and may leave the patient feeling
stigmatized.
Treatable and frequently undiagnosed
depressive and anxiety disorders often accom-
pany MUPS and compound disability (90).
Diagnosing these problems, linking diagnoses
to effective therapeutic options, and negotiat-
ing acceptable explanations and labels com-
prise appropriate care. Sometimes, however,
contested causation may increase the tendency
for providers to adopt psychological explana-
tions for MUPS in an effort to reassure the
patient. Patients experiencing MUPS, how-
ever, are seldom reassured and often outraged
with such explanations. Patients may feel the
provider has stolen hope for resolution by
blaming them for their symptoms and then
failing to offer acceptable treatment.
The other, equally unproductive extreme,
may also create distraction. In the context of
widely contested causation, the provider may
embark on a “no-stone-unturned” search for
a disease to explain the patient’s symptoms.
Although recognizing the diagnostic yield to
be diminishingly small, the provider–altruist
may run the test anyway. Paradoxically, this
approach may distract the provider and the
patient from appropriate treatment. This
occurs when the mystery, drama, and hope of
the diagnostic process captivate patient and
provider, leaving them spectating rather than
participating in collaborative management. It
may also lead to medically unnecessary
patient risk.
A final form of distraction sometimes
occurs when the provider believes that pub-
licly contested environmental causation is
unscientiﬁc, “political,” or frivolous. To pre-
vent “over-utilization” of expensive medical
resources in a manner that might nurture ille-
gitimate medical fears, the provider may pre-
maturely halt the process of care without
fostering a patient–provider partnership and
negotiating acceptable therapeutic options to
reduce disability.
Summary and Conclusions
We have reviewed the notion of MUPS, the
overlap of MUPS with several common but
poorly understood symptom syndromes, and
the predictable occurrence of MUPS after
controversial community, occupational, and
military exposures. We have asserted, based
on an emerging sociologic literature on com-
munity exposures and occupational illnesses,
that the adversarial social context that often
accompanies these environmental exposures,
a context we have referred to as “contested
causation,” may have an adverse effect on the
care of many individuals with MUPS. Factors
that allow social context to have a larger role
in MUPS care than for many well-defined
diseases are the uncertain nature of MUPS,
the extensive reliance of standard MUPS
therapies on a potentially tenuous
patient–provider partnership, and the routine
need to rely on subjective clinical assessments
that are often interpreted differently by the
patient than the provider.
Contested causation may adversely affect
MUPS care in any medical setting, making it
difﬁcult to translate the efﬁcacy of CBT and
GPA found in clinical trials into routinely
effective clinical practice. Even within a sup-
portive healthcare system offering an array of
collaborative patient management options, if
causation of MUPS is contested publicly
(e.g., in the news media) or privately (e.g.,
during an office visit), concerns regarding
dual agency, veracity, and trust often arise
and distract from the fundamental goal of
improving patient quality of life.
Occupational and military medicine may
be more vulnerable to these effects on MUPS
care than are other medical systems. Federal
medicine has embarked on an ambitious mul-
tipronged clinical and policy effort to address
military-related MUPS. These efforts include
referral programs, clinical practice guidelines,
information dissemination strategies, and sci-
entiﬁc and clinical centers of excellence. We
are playing a central role in these efforts, and
we think they are well placed given historical
evidence suggesting escalating societal and
patient concerns about enigmatic MUPS syn-
dromes with potential environmental etiolo-
gies. The theoretical probability that
contested causation poses additional threat to
effective MUPS care in occupational or mili-
tary settings means that we must demon-
strate, wherever possible, the efficacy of
MUPS care in these settings using carefully
designed, scientifically valid, randomized
controlled trials.
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